drugset / Trial / NCT04071639
Symptomatic Therapy for Patients With Huntington's Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.
Timeline
- Start
- 2020-03-12
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deutetrabenazine | Unknown | 6 mg | Oral |
| Subject | Haloperidol | Other / unclassified | 0.5 mg | Oral |
| Subject | Haloperidol | Other / unclassified | 2 mg | Oral |
| Subject | Idebenone | Small molecule | 30 mg | Oral |
| Subject | Risperidone | Other / unclassified | 1 mg | Oral |
| Subject | Sertraline | Small molecule | 50 mg | Oral |